Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $63.3 million versus the consensus estimate of $63.8 million.

Guidance:

The Company is increasing its full-year adjusted EBITDA range to $145 million to $155 million from the previous range of $125 million to $135 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.